- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04071990
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
December 8, 2023 updated by: University Hospital, Ghent
Impact of Involvement of the Family in the Cognitive Behavioral Group Therapy for Obsessive-Compulsive Disorder: a Randomized Controlled Trial.
With a lifetime prevalence of 1-3% Obsessive-Compulsive Disorder (OCD) is a chronic and disabling psychiatric disorder with considerable burden for the individual and society.
Cognitive-behavioural group therapy (CBGT) is effective in reducing the intensity of OCD symptoms and it improves the OCD patient's quality of life.
There is also growing evidence that family accommodation (FA) maintains and/or facilitates OCD symptoms, reinforces fear and avoidance behaviours in patients with OCD and is associated with family burden.
Considering the promising results of involvement of family in CBGT on OCD symptoms and FA, the current study aims at investigating the effects of the involvement of the family in a 12-week CBGT protocol on the OCD symptoms, FA, burden, QOL, anxiety and depressive symptoms in OCD patients and their live-in relatives.
Eighty patients with OCD and their live-in family members (partner, parent, sibling, …) between 18-65 years old will be included in this randomized controlled trial.
Patients and family members will be randomly assigned to CBGT with the involvement of family or to CBGT without involvement of family.
The primary goal of this study is to evaluate the effects of the involvement of live-in family members during a 12-week CBGT on OCD symptomatology and family accommodation during a 12-month follow-up period.
In a secondary stage, we will explore whether the involvement of live-in family members during a 12-week CBGT will ameliorate anxiety and depressive symptoms, QOL, family functioning and burden in the patients and their live-in family.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Participants will be recruited at the Centre for OCD at the Ghent University Hospital (UZ Gent) located in Belgium.
A group of 80 patients and 80 live-in family members (partner, parent, sibling), between 18 and 65 years old.
The patients with OCD will be selected based on the Diagnostic and Statistical Manual (DSM-5) diagnostic criteria for obsessive-compulsive disorder using the semi-structured Mini International Neuropsychiatric Interview (MINI screening version 7.0.2)(60).
Other inclusion criteria are (a) the OCD patient with a score of at least 16 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), (b) patient and family member fluent in Dutch and (c) both willing to attend all treatment sessions together.
To maximize the generalizability of our sample, we did not exclude patients if they had comorbid mood or anxiety disorders, as long as OCD was the principal diagnosis.
Patients and family members will be recruited before randomization, because the aim of this study is to investigate the impact of the involvement of the family in the CBGT.
At the start of the experiment we will ask patients and their family members to sign the informed consent.
Randomization occurs after oral and written informed consent and patients and family members will be notified about the treatment condition after randomization.
After randomization the patient and family member will be allocated to one of the two treatment arms: (a) CBGT with involvement of family of family-based CBGT (FB-CBGT) (intervention) or (b) CBGT without involvement of family (control).
The CBGT program exists of a fixed 12-week protocol, involving psycho-education, exposure and response prevention (ERP), cognitive restructuring, and the discussion about the family system.
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hannelore LN Tandt, MD
- Phone Number: +3293324394
- Email: hannelore.tandt@uzgent.be
Study Contact Backup
- Name: Gilbert MD Lemmens, MD, PhD
- Phone Number: +3293324394
- Email: gilbert.lemmens@uzgent.be
Study Locations
-
-
-
Ghent, Belgium, 9000
- Recruiting
- Ghent University Hospital
-
Contact:
- Hannelore LN Tandt, MD
- Phone Number: +3293324394
- Email: hannelore.tandt@uzgent.be
-
Contact:
- Gilbert MD Lemmens, MD, PhD
- Phone Number: +3293324394
- Email: gilbert.lemmens@ugent.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- the OCD patient with a score of at least 16 on Y-BOCS
- patient and family member fluent in Dutch
- patient and family member both willing to attend all treatment sessions together.
Exclusion Criteria:
- current severe suicidality
- current substance abuse
- psychotic symptoms and
- OCD treated with deep brain stimulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Family-based cognitive behavioral group therapy (FB-CBGT)
One family member of each patient will be involved during all 12 CBGT sessions.
The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g.
FA, burden, …) and homework exercises after each session.
|
CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
|
|
Placebo Comparator: Cognitive-behavioral group therapy (CBGT) without family
Each patient will be involved during all 12 CBGT sessions.
The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g.
FA, burden, …) and homework exercises after each session., without the involvement of family members.
|
CBGT for OCD patients, without involvement of family members
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Faster decrease and longer lasting improvement (less relapse) of OCD symptoms in patients
Time Frame: Y-BOCS will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
Improvement of OCD symptoms will be measured by the Y-BOCS
|
Y-BOCS will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
Faster decrease and longer lasting improvement of family accommodation in family members
Time Frame: The Family Accommodation Scale (FAS) will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
Improvement of family accommodation will be measured by the family accommodation scale (FAS)
|
The Family Accommodation Scale (FAS) will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A reduction in anxiety and depression in patients and family members
Time Frame: The HADS will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
The Hospital Anxiety and Depressive Scale (HADS) will be used to measure the presence of depression and anxiety and changes in depression and anxiety rates
|
The HADS will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
Increase of quality of life (QOL) in patients
Time Frame: The WHOQOL-BREF will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
The Quality of Life Questionnaire (WHOQOL-BREF) will be administered to assess the perceived quality of life and emotional well-being in patients
|
The WHOQOL-BREF will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
An improvement in family functioning measured by the SCORE-15 in patients and family members
Time Frame: The SCORE-15 will be completed at four time-points: at inclusion, after completion of the CBGT(an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
The Systemic Clinical Outcome and Routine Evaluation 15-item version (SCORE-15) will be administered to assess the outcome in systemic family therapy and other family-oriented services
|
The SCORE-15 will be completed at four time-points: at inclusion, after completion of the CBGT(an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
An improvement in family functioning measured by the BPNSFS in patients and family members
Time Frame: The BPNSFS will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
The Basic Psychological Need Satisfaction and Frustration Scale (BPNSFS) -addresses both need satisfaction and frustration in relationships.
Whereas need satisfaction is associated with well-being, need frustration is associated with ill-being.
Self-determination theory posits three universal psychological needs: autonomy; competence; and relatedness, and suggests that these must be present satisfactorily for people to maintain optimal performance and well-being.
|
The BPNSFS will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
An improvement in family functioning measured by the perceived criticism measure (PCM) in patients and family members
Time Frame: The PCM will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
The perceived criticism measure (PCM) consists of a 10-point Likert-type scale to describe a relative's degree of criticism of him of her.
The patients' perception on their relatives' behavior may be the proximal factor in expressed emotions relationship to treatment response and relapse.
This measure proved to be a strong predictor of outcome for outpatients with OCD.
|
The PCM will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
A decrease of burden in family members
Time Frame: The ZBI will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
Family burden will be evaluated with the Zarit Burden Interview (ZBI) 22-item version, a self-report measure.
The ZBI assesses the perceived burden in the caregivers of patients with psychiatric disorders.
|
The ZBI will be completed at four time-points: at inclusion, after completion of the CBGT (an average of 3 months post baseline) and at 6 and 12 months post CBGT
|
|
Evaluation therapeutic sessions
Time Frame: The SRS will be completed at 12 time-points: after all therapeutic sessions, 12 sessions in total, during 3 months
|
In order to assess how patients and family members evaluate the therapeutic relation, goals and topics, approach during the therapeutic session the Session Rating Scale (SRS V.3.0) will be administered.
|
The SRS will be completed at 12 time-points: after all therapeutic sessions, 12 sessions in total, during 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gilbert MD Lemmens, MD, PhD, Ghent University Hospital, University Ghent
- Principal Investigator: Kurt Audenaert, MD, PhD, Ghent University Hospital, University Ghent
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2019
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
August 2, 2019
First Submitted That Met QC Criteria
August 27, 2019
First Posted (Actual)
August 28, 2019
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC/2019/0419
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality issues but are available from the corresponding author upon reasonable request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Shanghai Pudong New Area Mental Health Center,...RecruitingObsessive Compulsive Disorder (OCD) | Obsessive - Compulsive DisorderChina
-
National Institute of Mental Health, Czech RepublicRecruitingObsessive-compulsive DisorderCzechia
-
Assiut UniversityNot yet recruitingSubstance Use | Substance Abuse Disorder | Obsessive Compulsive Disorder (OCD) | Obsessive Compulsive Behavior | Obsessive - Compulsive Disorder
-
ASST Fatebenefratelli SaccoFondazione IRCCS San Gerardo dei Tintori; Istittuo ricerca carattere Sceintifico...Enrolling by invitationObsessive - Compulsive DisorderItaly
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Shanghai Mental Health CenterNot yet recruitingObsessive - Compulsive DisorderChina
-
Adam FrankRecruitingObsessive - Compulsive DisorderUnited States
-
Taipei Veterans General Hospital, TaiwanRecruitingObsessive-Compulsive Disorder (OCD)Taiwan
-
VU University of AmsterdamUniversity of Bern; Stockholm University; Thomas More University of Applied SciencesNot yet recruitingObsessive Compulsive Disorder (OCD)Sweden, Belgium, Netherlands, Switzerland
-
Butler HospitalNot yet recruitingPostpartum Obsessive Compulsive Disorder
Clinical Trials on FB-CBGT
-
Norwegian University of Science and TechnologyHelse Nord-Trøndelag HFCompletedLow Back PainNorway
-
1ST Biotherapeutics, Inc.Not yet recruiting
-
Forte Biosciences, Inc.Terminated
-
Donald B. Kohn, M.D.California Institute for Regenerative Medicine (CIRM)Completed
-
1ST Biotherapeutics, Inc.CompletedParkinson's DiseaseUnited States
-
Hopital MontfortUniversity of Ottawa; Ontario Mental Health FoundationCompletedSocial Anxiety DisorderCanada
-
Forte Biosciences, Inc.CompletedAtopic DermatitisUnited States
-
Goethe UniversityJohann Wolfgang Goethe University Hospital; Philipps University MarburgNot yet recruitingDepression - Major Depressive DisorderGermany
-
University Medical Center GroningenActive, not recruiting